Abstract #3747

Monitoring neoadjuvant chemotherapy in breast cancer patients using CEST and 31P-MRS at 7 tesla

Erwin Krikken¹, Vitaliy Khlebnikov¹, Moritz Zaiss², Wybe J.M. van der Kemp¹, Tijl A. van der Velden¹, Hanneke W.M. van Laarhoven³, Dennis W.J. Klomp¹, and Jannie P. Wijnen¹

¹Radiology, UMC Utrecht, Utrecht, Netherlands, ²Max Planck Institute for Biological Cybernetics, Tubingen, Germany, ³Oncology, Amsterdam Medical Center, Amsterdam, Netherlands

Treatment monitoring is of importance for breast cancer patients receiving systemic therapy. Metabolic imaging methods such as CEST and³¹P-MRS may have potential to predict treatment efficacy in an early stage of the treatment. In this study we assessed the amide proton transfer (APT) signal and the pH change in breast cancer patients before and after the first cycle of neoadjuvant chemotherapy to explore the relation between APT and pH. We observed changes in both the APT signal and the pH between the two measurements. These changes may serve as biomarkers for predicting treatment response to NAC in an early stage.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.